Philadelphia and Vancouver, British Colombia, October 3, 2025 (Globe Newswire) -Briacell Therapeutics Corp. (NASDAQ: BCTX, BCTXW, BCTXZ) (TSX: BCT) (Briacell) (Briacell or Company, a clinical biotechnological company that develops a brand new Enzo. Presentation of the preclinic data of BriahTS+ at a poster in the Immunotherapy Society (SITC) 40tour The annual meeting of the anniversary, consisting of November 7-9, 2025 in the National Harbor, Maryland. The details are below.
Headline: Overlooking cancer vaccines: Bria-ts+ integrates trained congenital immunity and adaptive memory to overcome immune resistance
Abstract number: 353
Location: Exhibition and conference -Prince George ABC.
Date: Friday, November 7, 2025
After the presentation, a copy of the poster will be available on https://briacell.com/scientific-publications/Field
About Briacell Therapeutics Corp.
Briacell is a biotechnological company of the clinical stage, which develops new immunotherapy for transformation of cancer treatment. More information is available on https://briacell.com/Field
Safe harbor
This press release contains “promising statements” that are subject to significant risks and uncertainty. All statements, except for the statements of the historical fact contained in this press release, are promising statements. The advanced statements contained in this press release can be defined using such words as “expectation”, “believe”, “contemplation”, “could”, “evaluation”, “expect”, “intend”, “look”, “can”, “maybe”, “potential”, “potential”, “predict”, “project”, “target”, “target”, “aiming”, “should”, “should”, “should”, “Negative”, “negative” or “expenses”, “sights”, “terms”, “say”, “terms”, “aim”, “tell”, “negative”, “aim”, “aim”, “negative” or “terms”. Not all promising statements contain these words. Advanced statements, including applications for the submission of a poster at the annual meeting of the SITC 2025 and the content of such a poster, are based on the current expectations of the Briacon and are subject to uncertainty, risks and assumptions that are difficult to predict. In addition, certain forecast statements are based on assumptions about future events that may not be accurate. Thhe and Other risks and uncertainties are described More Fully Under the Heading “Risks and Uncertainties” in the Company's Most Recent Management's Discussion and Analysis,, Analysis, Under The Heading “Risk Factors” in the Company's Most Recent annal information form, and under “Risks and Uncertainties” In the Company's Other Filings with the Canadian Securities Regulatory Authorites and the us Securities and Exchange Commission, All of Which Avalable Under the Company's Profiles on Sedar+ AT www.Sedarplus.ca and on Edgar in www.sec.govThe field of statements about the prospects contained in this announcement are made on this date, and Briacell Therapeutics Corp. It does not fulfill the obligation to update such information, with the exception of cases required in accordance with applicable law.
Neither the Toronto stock exchange, nor its provider of regulation services (as this term is determined in the policy of the Toronto Stock Exchange), are responsible for the adequacy or accuracy of this issue.
Contact information
Company contact:
William V. Williams, MD
President and General Director
1-888-485-6340
[email protected]
Contact associated with investors:
[email protected]
